Posttraumatic Stress Disorder - Trauma Focused Therapy and Medication

Key Points

• Confirm a qualifying trauma and all required PTSD symptom clusters rather than diagnosing from nightmares alone.
• Trauma-focused psychotherapy is preferred over medication when feasible and acceptable.
• Sertraline, paroxetine, and venlafaxine are evidence-supported pharmacologic options.
• Prazosin may help trauma-related nightmares in selected patients but is not a complete PTSD treatment.
• Benzodiazepines are discouraged in PTSD because harms and interference with recovery outweigh short-term anxiolysis.
• Assess suicide risk, ongoing victimization, substance use, depression, TBI, and sleep disorders.
• Use symptom scales to track severity, but do not substitute them for diagnostic interviewing.
• Treat co-occurring substance use disorders concurrently rather than sequentially.

Algorithm

1. Establish trauma exposure, symptom duration, clusters, and functional impact.
2. Assess immediate safety, suicidality, self-harm, aggression, ongoing abuse, intoxication, and withdrawal.
3. Screen for depression, substance use, TBI, chronic pain, and sleep disorders.
4. Offer evidence-based trauma-focused psychotherapy as the preferred core treatment.
5. If medication is desired or psychotherapy is unavailable, select sertraline, paroxetine, or venlafaxine based on patient factors.
6. Target persistent nightmares or insomnia with specific adjunctive strategies rather than sedative polypharmacy.
7. Reassess avoidance, functioning, substance use, and suicide risk longitudinally.
8. Continue effective treatment and create a relapse plan for anniversaries, triggers, and major stressors.

Clinical Synopsis & Reasoning

PTSD should be considered when symptoms persist beyond the immediate post-trauma period and cluster across intrusion, avoidance, negative alterations in cognition or mood, and arousal/reactivity. Intrusive memories, nightmares, flashbacks, physiologic reactivity to reminders, avoidance of people or situations, emotional numbing, guilt, detachment, hypervigilance, exaggerated startle, sleep disruption, and irritability are common. The diagnostic interview should clarify the qualifying trauma, timing, symptom clusters, dissociation, functional impairment, and whether symptoms are better explained by substance use, traumatic brain injury, psychosis, panic, major depression, or another disorder. Acute stress reactions in the first month after trauma are not automatically PTSD.

Safety assessment is central. Ask about suicidal thoughts, self-harm, aggression, intimate partner violence, ongoing exposure to the perpetrator, housing instability, and substance use. Veterans and survivors of repeated interpersonal trauma may have chronic pain, insomnia, depression, alcohol misuse, and medical comorbidity that complicate recovery. Screening instruments such as the PCL-5 can quantify symptom burden and follow progress, but diagnosis requires clinical assessment. Routine laboratory or imaging studies do not diagnose PTSD; testing is targeted to medical symptoms, head injury, intoxication or withdrawal, endocrine disease, or medication effects suggested by the presentation.

Treatment Strategy & Disposition

The 2023 VA/DoD guideline recommends individual trauma-focused psychotherapies such as prolonged exposure, cognitive processing therapy, and eye movement desensitization and reprocessing over medication when these treatments are available and acceptable. Effective treatment involves structured processing of traumatic memories and reduction of avoidance, not simply supportive discussion. Therapy should proceed at a tolerable pace with attention to safety and stabilization, but chronic avoidance of trauma-focused work can preserve symptoms.

When pharmacotherapy is chosen, sertraline, paroxetine, and venlafaxine have the strongest guideline support. Medication choice should account for prior response, pregnancy considerations, sexual adverse effects, blood pressure, comorbid depression or pain, and withdrawal risk. Prazosin may be considered for PTSD-associated nightmares in selected patients, but it is not recommended as general monotherapy for all PTSD symptoms. Benzodiazepines are recommended against because they do not treat core PTSD pathology and can worsen dependence, cognitive problems, falls, and interference with exposure-based learning. Cannabis is not an evidence-based PTSD treatment. Treat comorbid alcohol or opioid use disorder concurrently rather than waiting for complete PTSD remission. Persistent severe insomnia can be addressed with CBT-I while trauma-focused treatment continues.

Epidemiology / Risk Factors

• PTSD can occur after combat, sexual assault, interpersonal violence, disasters, serious accidents, medical trauma, and other qualifying exposures.
• Risk is increased by prior trauma, limited social support, severe or repeated exposure, and comorbid psychiatric illness.
• Many trauma-exposed people do not develop PTSD, so trauma history alone is not diagnostic.
• Symptoms may begin soon after trauma or become clinically apparent later.

Investigations

Nightmare Options

Pharmacology

Prognosis / Complications

• Many patients improve substantially with evidence-based trauma-focused therapy.
• Chronic untreated PTSD is associated with depression, substance misuse, relationship problems, occupational impairment, and elevated suicide risk.
• Residual sleep disturbance and avoidance may persist even when overall symptom burden improves.
• Relapse or symptom flares can occur with new trauma, anniversaries, loss, pain exacerbations, or substance recurrence.

Patient Education / Counseling

• Explain that avoidance often provides short-term relief while maintaining PTSD over time.
• Discuss the differences between trauma-focused psychotherapy, supportive counseling, and medication so expectations are realistic.
• Encourage safe social support, regular sleep, physical activity, and reduction of alcohol or nonprescribed sedatives.
• Provide crisis instructions for suicidal thinking, escalating violence risk, severe dissociation, or inability to maintain safety.
• Respect patient control over pacing and disclosure while still recommending evidence-based treatment.

Notes

PTSD treatment should be organized around recovery of function and reduction of avoidance. A patient may report fewer flashbacks while still avoiding driving, intimacy, work, sleep, or medical care. Follow-up should therefore ask what life activities have reopened as well as how symptom scores have changed. Trauma-focused treatments are structured interventions and should be delivered by clinicians trained in the method.

Medication is usually adjunctive rather than curative. If a patient has little improvement after an adequate evidence-based trial, revisit adherence, diagnosis, trauma-focused therapy access, alcohol or drug use, ongoing victimization, sleep apnea, chronic pain, and bipolar or psychotic symptoms. Persistent severe symptoms, recurrent suicidality, complex dissociation, or diagnostic uncertainty merit specialty mental health involvement.

References

1. VA/DoD Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder, 2023 — Link